Alteration of inflammatory mediators in patients with obstructive sleep apnea.

SESSION TITLE: Comorbidities of OSA PostersSESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: The aim of our study was to determine the relationship between some inflammatory mediators, Obstructive Sleep Apnea (OSA) and the Metabolic Syndrome (MS).

METHODS: A total of 140 patients with clinical suspicion of OSA were studied from January 2007 to January 2008. Anthropometric data, smoking history and treatment were collected in all cases. Daytime sleepiness was measured by the Epworth Scale. OSA was determined by a full polysomnography, and AHI cut-off of 10 events/hour defined the presence of OSA. The morning after polysomnography a venous sample was obtained. Blood glucose, total cholesterol, HDL cholesterol and triglycerides were determined by standard methods. IL-6, TNF- α and adiponectin were analized by ELISA.

RESULTS: OSA was diagnosed in 104 patients (74.3%). A total of 72.1% suffered severe OSA, 19,2% moderate and 9,6% mild. The mean age was 54.8 ± 11.7 yrs and 74.3% were male. Statistical signification was obtained for all anthropometric data (BMI, BP and waist circumference), for the Epworth scale, and also for glucose and HDL cholesterol. MS was diagnosed in 85 (60%) patients (73 OSA and 12 non OSA). There were no significant differences in IL-6, TNF-α and Adiponectin levels in patients with OSA and non OSA. However, within the OSA group, MS patients had significantly higher IL-6 levels than those without MS (p< 0.01). IL-6 levels were significantly correlated with AHI (r = 0.3, p = 0.01), but not adiponectin nor TNF-α levels.

CONCLUSIONS: In our population, OSA is not associated with changes in inflammatory mediators levels (IL-6, TNF-α and adiponectin). However, the coexistence of MS increases inflammation in OSA.

CLINICAL IMPLICATIONS: OSA and MS have been widely studied as risk factors for cardiovascular events. Evaluating the behavior of inflammatory mediators at different levels of OSA and in MS, as well as its response after treatment with CPAP, would help us to see if they are good markers of treatment-response.

DISCLOSURE: The following authors have nothing to disclose: Ana Lapuente Torrents, Bienvenido Barreiro, Montserrat Alsina, Lourdes Lozano, Josep Lluis HerediaNo Product/Research Disclosure Information.